As only 20–30% of breast carcinomas overexpress the HER2 antigen [34], HER2 testing is currently required prior to patient enrollment for trastuzumab therapy, and several companion diagnostic assays for HER2 testing have been approved by the Food and Drug Administration (FDA) [33]. The gene discussed is ERBB2; the disease is breast carcinoma.